Sensile Medical, a subsidiary of Gerresheimer AG, has signed a contract with the Swiss biopharma-ceutical company SQ Innovation AG for the development, market launch and mass production of a micro pump for the treatment of edema in heart failure.
“Our micro pump technology is highly advanced and very competitive. It can be used for a variety of treatments across medical conditions,” said Dietmar Siemssen, CEO of Gerresheimer AG. “The new SQ Innovation agreement illustrates the attractiveness of our micro pump technology. The pipeline of projects for the micro pump is very promising and we continue to see significant potential in this unique technology.”
The market launch of the SQ Innovation product will take place after completion of development and obtaining market authorization. Sensile Medical’s micro pump for Parkinson’s treatment has already been approved for the European market in September 2018 and has been launched.
Gerresheimer has started several projects with pharma customers for usage of the micro pump in various therapy areas, which illustrate the future potential.
For information about SQ Innovation AG visit http://furosemide.com.